FDA
-
-
-
-
-
-
-
Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use
-
-
-
-
-
-
-
Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
-
-
-
-
-
-
-
Legend Biotech Reports Second Quarter 2025 Results and Recent Highlights
-
-
-
-
-
-
-
Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT
-
-
-
-
-
-
-
CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma
-
-
-
-
-
-
-
Dialogue with CGT Leaders! You Are Invited to Join the "2024 GenScript Biotech Global Forum•London" to Discuss the Future Together
-
-
-
-
-
-
-
Citi Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
-
323,538 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

